{"id":"NCT00806195","sponsor":"Novartis","briefTitle":"Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","officialTitle":"A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2011-03","completion":"2011-11","firstPosted":"2008-12-10","resultsPosted":"2013-07-09","lastUpdate":"2013-07-09"},"enrollment":7744,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningitis","Meningococcal Infection"],"interventions":[{"type":"BIOLOGICAL","name":"MenACWY-CRM197","otherNames":[]},{"type":"BIOLOGICAL","name":"DTaP (Diptheria, Tetanus, Pertussis) Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Hib (Haemophilus influenza b) Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"IPV (Inactivated Polio Vaccine) Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Pneumococcal conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"MMR (Measles, Mumps, and Rubella) Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Varicella Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Hepatitis A Virus","otherNames":[]}],"arms":[{"label":"MenACWY-CRM197 + Routine Vaccines (Non-Detailed)","type":"EXPERIMENTAL"},{"label":"Routine Vaccines (Non-Detailed)","type":"ACTIVE_COMPARATOR"},{"label":"MenACWY-CRM197 + Routine Vaccines (Detailed)","type":"EXPERIMENTAL"},{"label":"Routine Vaccines (Detailed)","type":"ACTIVE_COMPARATOR"},{"label":"MenACWY-CRM197 + Routine Vaccines (All)","type":"EXPERIMENTAL"},{"label":"Routine Vaccines (All)","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this phase 3b study is to evaluate the safety and tolerability of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants","primaryOutcome":{"measure":"Percentages of Subjects With At Least One Severe Systemic Reaction After Any Vaccination","timeFrame":"15 minutes to Day 7 after any vaccination administered at 2, 4, 6 and 12 months of age","effectByArm":[{"arm":"MenACWY-CRM197 + Routine Vaccines (Detailed)","deltaMin":16,"sd":null},{"arm":"Routine Vaccines (Detailed)","deltaMin":13,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"55 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":15},"locations":{"siteCount":153,"countries":["United States","China","Costa Rica","Guatemala","Panama","Peru"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":354,"n":5760},"commonTop":["Upper Respiratory Tract Infection","Otitis Media","Pyrexia","Irritability","Diarrhoea"]}}